Search results for "Tissue Plasminogen Activator"

showing 10 items of 48 documents

Annexin A2-Mediated Plasminogen Activation in Endothelial Cells Contributes to the Proangiogenic Effect of Adenosine A2A Receptors

2021

Adenosine A2A receptor mediates the promotion of wound healing and revascularization of injured tissue, in healthy and animals with impaired wound healing, through a mechanism depending upon tissue plasminogen activator (tPA), a component of the fibrinolytic system. In order to evaluate the contribution of plasmin generation in the proangiogenic effect of adenosine A2A receptor activation, we determined the expression and secretion of t-PA, urokinase plasminogen activator (uPA), plasminogen activator inhibitor-1 (PAI-1) and annexin A2 by human dermal microvascular endothelial cells stimulated by the selective agonist CGS-21680. The plasmin generation was assayed through an enzymatic assay a…

0301 basic medicineFarmacologiaAngiogenesisPlasminmedicine.medical_treatmentVasodilatadorsAdenosine A2A receptorRM1-950030204 cardiovascular system & hematologyTissue plasminogen activatormicrovascular endothelial cells03 medical and health scienceschemistry.chemical_compound0302 clinical medicineFibrinolysismedicinePharmacology (medical)urokinase plasminogen activatorPharmacologytissue plasminogen activatorChemistryBrief Research Reportannexin A2adenosine receptorsCell biology030104 developmental biologyPlasminogen activator inhibitor-1plasminogen activator inhibitor-1Therapeutics. PharmacologyPlasminogen activatorProteïnesAnnexin A2medicine.drug
researchProduct

Lipoprotein receptor loss in forebrain radial glia results in neurological deficits and severe seizures.

2020

The Alzheimer disease-associated multifunctional low-density lipoprotein receptor-related protein-1 is expressed in the brain. Recent studies uncovered a role of this receptor for the appropriate functioning of neural stem cells, oligodendrocytes, and neurons. The constitutive knock-out (KO) of the receptor is embryonically lethal. To unravel the receptors' role in the developing brain we generated a mouse mutant by specifically targeting radial glia stem cells of the dorsal telencephalon. The low-density lipoprotein receptor-related protein-1 lineage-restricted KO female and male mice, in contrast to available models, developed a severe neurological phenotype with generalized seizures duri…

0301 basic medicineMaleEpendymoglial CellsBiology03 medical and health sciencesCellular and Molecular NeuroscienceEpilepsyMice0302 clinical medicineProsencephalonSeizuresmedicineAnimalsReceptors LipoproteinLipoprotein receptor-related proteinmedicine.diseaseNeural stem cellLipoproteins LDL030104 developmental biologymedicine.anatomical_structureNeurologyAstrocytesTissue Plasminogen ActivatorForebrainFemaleSynaptic signalingStem cellPostsynaptic densityNeuroscience030217 neurology & neurosurgeryAstrocyteGliaREFERENCES
researchProduct

Measurement of Bradykinin Formation and Degradation in Blood Plasma: Relevance for Acquired Angioedema Associated With Angiotensin Converting Enzyme …

2020

Bradykinin (BK)-mediated angioedema (AE) states are rare acquired or hereditary conditions involving localized edema of the subcutaneous and submucosal tissues. Citrated plasma from healthy volunteers or patients with hereditary angioedema (HAE) with normal level of C1-inhibitor (C1-INH) was used to investigate pathways of BK formation and breakdown relevant to AE physiopathology. The half-life of BK (100 nM) added to normal plasma was 34 s, a value that was increased ~12-fold when the angiotensin converting enzyme (ACE) inhibitor enalaprilat (130 nM) was added (enzyme immunoassay measurements). The BK half-life was similarly increased ~5-fold following 2 daily oral doses of enalapril malea…

0301 basic medicinemedicine.medical_specialtykallikreinsPlasminBradykininTissue plasminogen activator03 medical and health scienceschemistry.chemical_compound0302 clinical medicineInternal medicinemedicineB2 receptorsOriginal ResearchplasminFactor XIIlcsh:R5-920tissue plasminogen activatorAngioedemabiologyhereditary angioedema with normal C1 inhibitor levelAngiotensin-converting enzymeGeneral MedicineKallikreinmedicine.disease030104 developmental biologyEndocrinology030228 respiratory systemchemistryHereditary angioedemabiology.proteinMedicinemedicine.symptombradykininlcsh:Medicine (General)medicine.drugFrontiers in Medicine
researchProduct

Coronavirus Disease 2019–Associated Coagulopathy

2021

Patients with the severe form of coronavirus disease 2019 (COVID-19) have been frequently found to suffer from both arterial and venous thrombotic events due to the perpetuation of a hypercoagulable state. This phenomenon, termed COVID-19-associated coagulopathy (CC), is now considered a major component of the pathophysiology of this novel infectious disease, leading to widespread thrombosis. While at first, the vascular insults may be limited to the pulmonary microvasculature, as the disease progresses, systemic involvement occurs, culminating in distant organ thrombosis and multi-organ dysfunction syndrome. In this review article, we discuss recent insights into the pathophysiologic mecha…

ARDSPAI-1 Plasminogen Activator Inhibitor 1VTE venous thromboembolismDiseaseReview030204 cardiovascular system & hematologyCoronavirus Disease 20190302 clinical medicineCoagulopathy030212 general & internal medicineDIC disseminated intravascular coagulationDisseminated intravascular coagulationCOVID-19 Coronavirus disease 2019DVT deep vein thrombosisGeneral MedicineBlood Coagulation DisordersThrombosisICU intensive care unitTMA thrombotic microangiopathyDisease ProgressionCoronavirus Disease 2019 COVID-19 CoagulopathyVWF von Willebrand factormedicine.medical_specialtyThrombotic microangiopathyACE2 angiotensin-converting enzyme 2SARS-CoV-2 severe acute respiratory syndrome coronavirus 203 medical and health sciencesmedicineCoagulopathyHumansIntensive care medicineLY30 lysis at 30 minutesARDS acute respiratory distress syndromeHemostasisNO nitric oxideCoagulationbusiness.industrySARS-CoV-2COVID-19Thrombosismedicine.diseasetPA tissue plasminogen activatorReview articleIL interleukinCoronavirusVascular DisorderPE pulmonary embolismTF tissue factorbusinessCC COVID-associated coagulopathyMayo Clinic Proceedings
researchProduct

Kallikrein–kinin system and fibrinolysis in hereditary angioedema due to factor XII gene mutation Thr309Lys

2009

In a subgroup of hereditary angioedema (HAE) patients with normal C1-esterase inhibitor levels, HAE is caused by a Thr309Lys mutation in the coagulation factor XII (F12) gene. The aim of this study was to examine elements of the kallikrein-kinin system ('contact system') and the downstream-linked coagulation, complement and fibrinolytic systems in the plasma of six patients with HAE caused by the Thr309Lys mutation and healthy probands. Blood samples were taken from participants during the symptom-free interval between attacks. Samples were analyzed for activity and concentrations of components of the kallikrein-kinin system and linked enzyme systems. The mean FXII clotting activity was 90%…

AdultMalemedicine.medical_specialtyAdolescentMutation MissenseKininsCoagulation Factor XIIFactor XIIaGene mutationYoung AdultInternal medicinemedicineHumansPoint MutationHereditary Angioedema Type IIIComplement Pathway ClassicalAgedAged 80 and overFactor XIIAngioedemaChemistryFibrinolysisDextran SulfateAngioedemas HereditaryPrekallikreinPrekallikreinBlood ProteinsHematologyGeneral MedicineMiddle AgedSilicon Dioxidemedicine.diseaseEnzyme ActivationEndocrinologyAmino Acid SubstitutionChromogenic CompoundsCoagulationTissue Plasminogen ActivatorHereditary angioedemaImmunologyFemaleKallikreinsmedicine.symptomcirculatory and respiratory physiologyBlood Coagulation & Fibrinolysis
researchProduct

Increased plasminogen activator inhibitor antigen levels in diabetic patients with stable angina

1991

PAI-1 antigen, tPA antigen and thrombin - antithrombin III complexes (TAT) levels were measured in 10 males with stable angina and type-II diabetes mellitus and in 16 males with stable angina without diabetes or other risk factors (hyperfibrinogenaemia, hyperlipidaemia, diabetes, hypertension, smoking and obesity) known to increase PAI levels. Ten healthy men of equivalent age served as controls. Because only diabetics with coronary artery disease (CAD) showed a decreased fibrinolytic capacity, a second study was performed on the 16 non-diabetic CAD patients to determine whether submaximal workload induces significant changes of tPA and PAI levels. TAT levels were increased in CAD, and sign…

AdultMalemedicine.medical_specialtyAntithrombin IIICoronary DiseaseStable anginaAngina PectorisFibrin Fibrinogen Degradation ProductsCoronary artery diseaseThrombinAntigenDiabetes mellitusInternal medicinemedicineHumanscardiovascular diseasesAgedbusiness.industryFibrinolysisPlasminogen activator inhibitor antigenAntithrombinFibrinogenHematologyGeneral MedicineMiddle Agedmedicine.diseaseObesityPlasminogen InactivatorsEndocrinologyDiabetes Mellitus Type 2Tissue Plasminogen ActivatorExercise TestbusinessPeptide Hydrolasesmedicine.drugBlood Coagulation & Fibrinolysis
researchProduct

Fibrinolysis in hypertriglyceridaemic subjects in response to venous occlusion.

1993

We have measured various fibrinolytic and coagulation parameters (t-PA antigen, PAI, fibrinogen, plasminogen and factor VII) before and after 10 min of venous occlusion in 20 hypertryglyceridaemic subjects (twelve males and eight females, age 38 +/- 4 years, body mass index 23 +/- 1.5) and 20 healthy normal subjects, matched for sex (twelve males and eight females), age (37 +/- 3.5 years) and body mass index (22.8 +/- 1.4). At rest, t-PA:Ag, PAI, fibrinogen, plasminogen and factor VII were significantly (P < 0.005) higher in hypertriglyceridaemic subjects than in normal controls. After venous occlusion, the increase in all parameters except t-PA:Ag was more marked in the patient group than …

AdultMalemedicine.medical_specialtyPathologymedicine.medical_treatmentFibrinogenHyperlipoproteinemia Type IVVeinschemistry.chemical_compoundAntigenInternal medicineOcclusionFibrinolysisPlasminogen Activator Inhibitor 1medicineHumansFactor VIIbusiness.industryFibrinolysisHypertriglyceridemiaFibrinogenPlasminogenHematologyGeneral MedicineFactor VIIMiddle Agedmedicine.diseaseConstrictionLipidsEndocrinologyApolipoproteinsCoagulationchemistryTissue Plasminogen ActivatorFemalebusinessBody mass indexmedicine.drugBlood coagulationfibrinolysis : an international journal in haemostasis and thrombosis
researchProduct

An unusual presentation of massive pulmonary embolism mimicking septal acute myocardial inferction treated with tenecteplase

2007

A 31-year-old man (175 cm, 82 kg) was referred to the emergency department 2 h after the sudden onset of acute dyspnea. Immediate ECG showed sinus tachycardia with ST elevations from V1 through V2 and a diagnosis of septal acute myocardial infarction was made. ECG on admission to the cardiology department showed the same results plus the S1-Q3-T3 pattern. Echocardiogram revealed a normally contracting left ventricle, a distended right ventricle with free wall hypokinesia and displacement of the interventricular septum towards the left ventricle. Thrombolytic therapy with tenecteplase 8000 IU and heparin 5000 IU was administered 5-10 min after hospitalisation and the patient was haemodynamic…

AdultMalemedicine.medical_specialtySettore MED/09 - Medicina InternaSinus tachycardiaMyocardial InfarctionTenecteplaseDiagnosis DifferentialElectrocardiographyFibrinolytic AgentsInternal medicinemedicineHumansThrombolytic Therapycardiovascular diseasesMyocardial infarctionInterventricular septumtenecteplasebusiness.industrymassive pulmonary embolismElectrocardiography in myocardial infarctionHematologymedicine.diseasePulmonary embolismmedicine.anatomical_structureVentricleTissue Plasminogen ActivatorCardiologySeptum of BrainRadiologyMyocardial infarction diagnosismedicine.symptomCardiology and Cardiovascular MedicinebusinessPulmonary Embolismmedicine.drug
researchProduct

Immediate versus delayed facilitated percutaneous coronary intervention. A pilot study

2005

The study was aimed to investigate the outcomes in patients initially successfully treated pharmacologically and immediate PCI <2 hours, and in patients initially successfully treated with pharmacological therapy and delayed PCI (12-72 hours). All patients had to have successful reperfusion, to receive the combination of a standard abciximab infusion plus half dose rtPA. Similar results were observed in both groups. Delayed PCI group showed a favorable trend in restenosis and bleedings (ns) and a significant reduced angiographic evidence of thrombus formation in IRA. Our very preliminary data suggest the safety and possible use of delayed facilitated PCI in patients with STEMI. The studied …

AdultMalemedicine.medical_specialtyTime Factorsmedicine.medical_treatmentAbciximabMyocardial InfarctionMyocardial IschemiaEligibility DeterminationMyocardial ReperfusionPilot ProjectsAcute myocardial infarctionElectrocardiographyImmunoglobulin Fab FragmentsRestenosisInternal medicinemedicineAbciximabHumansIn patientcardiovascular diseasesThrombusAngioplasty Balloon CoronaryFacilitated pciDelayed percutaneous coronary interventionPharmacologybusiness.industryPatient SelectionPercutaneous coronary interventionAntibodies MonoclonalMiddle Agedmedicine.diseaseSurvival RateGIIb/IIIa inhibitorssurgical procedures operativeTreatment OutcomeTissue Plasminogen ActivatorConventional PCICardiologyFemaleCardiology and Cardiovascular MedicinebusinessFacilitated percutaneous coronary interventionTIMIPlatelet Aggregation InhibitorsCombined therapymedicine.drug
researchProduct

Telemedicine for the acute management of stroke in Burgundy, France: an evaluation of effectiveness and safety

2016

Background In the context of the development of telemedicine in France to address low thrombolysis rates and limited stroke infrastructures, a star-shaped telestroke network was implemented in Burgundy (1.6 million inhabitants). We evaluated the safety and effectiveness of this network for thrombolysis in acute ischemic stroke patients. Methods One hundred and thirty-two consecutive patients who received intravenous thrombolysis during a telemedicine procedure (2012–2014) and 222 consecutive patients who were treated at the stroke center of Dijon University Hospital, France (2011–2012) were included. Main outcomes were the modified Rankin scale (mRS) score and case fatality at 3 months. Com…

AdultMalemedicine.medical_specialtythrombolysismedicine.medical_treatmentContext (language use)030204 cardiovascular system & hematologyLogistic regressionBrain Ischemia03 medical and health sciences0302 clinical medicineFibrinolytic AgentsModified Rankin ScaleNeoplasmsCase fatality ratemedicineHumansThrombolytic TherapyIntensive care medicineStrokeAgedAged 80 and overbusiness.industry[ SDV.SPEE ] Life Sciences [q-bio]/Santé publique et épidémiologieThrombolysisOdds ratioMiddle Agedmedicine.diseasestrokeConfidence interval3. Good healthTreatment OutcomeNeurologyTissue Plasminogen ActivatorEmergency medicineoutcomeFemale[SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologieNeurology (clinical)FrancePatient Safetyprognosistelemedicinebusiness030217 neurology & neurosurgery
researchProduct